BTCS Inc. Acquires 3,450 Ether (ETH) for $8.42M, Expanding Ethereum Holdings to 12,500 ETH
As of May 16, 2025, BTCS holds approximately 12,500 ETH, up from 9,063 ETH at the end of Q1 2025-an increase of approximately 38%. This growth contributed to the fair market value of the Company's total cryptocurrency holdings and cash reaching approximately $38.42 million, representing an 88% increase since the start Q2 2025.
'Ethereum remains at the core of our blockchain infrastructure strategy,' said Charles Allen, Chief Executive Officer of BTCS. 'By expanding our ETH position, we are strengthening the foundation that allows us to scale validator operations, grow staking revenue, and drive long-term value for shareholders.'
About BTCS:
BTCS Inc. (NASDAQ: BTCS) is a U.S.-based blockchain infrastructure technology company currently focused on driving scalable revenue growth through its blockchain infrastructure operations. BTCS has honed its expertise in blockchain network operations, particularly in block building and validator node management. Its branded block-building operation, Builder+, leverages advanced algorithms to optimize block construction for on-chain validation, thus maximizing gas fee revenues. BTCS also supports other blockchain networks by operating validator nodes and staking its crypto assets across multiple proof-of-stake networks, allowing crypto holders to delegate assets to BTCS-managed nodes. In addition, the Company has developed ChainQ, an AI-powered blockchain data analytics platform, which enhances user access and engagement within the blockchain ecosystem. Committed to innovation and adaptability, BTCS is strategically positioned to expand its blockchain operations and infrastructure beyond Ethereum as the ecosystem evolves. Explore how BTCS is revolutionizing blockchain infrastructure in the public markets by visiting www.btcs.com.
Forward-Looking Statements:
Certain statements in this press release constitute 'forward-looking statements' within the meaning of the federal securities laws, including statements regarding investment opportunities from Ethereum, growing staking revenue, and driving long-term value for shareholders. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend' or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon assumptions and are subject to various risks and uncertainties, including without limitation regulatory issues (including, but not limited to, potential SEC enforcement actions, regulatory changes affecting DeFi protocols, and state regulatory requirements), cybersecurity risks, technological challenges, market adoption risks, changes in blockchain protocols, continued volatility in the cryptocurrency markets, smart contract risks, liquidation risks associated with DeFi borrowing, and other risks inherent to blockchain technology and cryptocurrency operations, as well as risks set forth in the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2024 which was filed on March 20, 2025. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements, whether as a result of new information, future events, or otherwise, except as required by law.
LinkedIn: https://www.linkedin.com/company/nasdaq-btcs
Facebook: https://www.facebook.com/NasdaqBTCS
Email: [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252578
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Bitcoin, Ethereum, XRP tumble on shocking inflation report
Bitcoin, Ethereum, XRP tumble on shocking inflation report originally appeared on TheStreet. The personal consumption expenditures (PCE) price index rose 0.3% on a monthly basis and 2.6% on a year-to-year (YoY) basis in June. Core PCE, which excludes volatile food and energy prices, in June was up 0.3% on a monthly basis and 2.8% on an annual basis. The crypto market immediately dipped in reaction to the news. Bitcoin fell 0.11% in an hour to $118,327.92, Ethereum fell 0.75% to $3,815.08, and XRP fell 0.81% to $3.11. BNB fell 0.56% to $795.14 and SOL also fell 1.25% to $ Bureau of Economic Analysis defines the PCE price index as a key inflation indicator that measures the prices that people living in the U.S., or those buying on their behalf, pay for goods and services. The index is known for capturing inflation across a wide range of consumer expenses and reflecting changes in consumer behavior. The Federal Reserve decided to keep the interest rates unchanged at 5.25%-5.5% at its July 30 meeting, and Chair Powell didn't indicate any potential cut in interest rates in September, saying the central bank will factor in more data and information until it makes the rate decision in the next Sep. 16-17 meeting. Since PCE is one of the most closely watched inflation indicators by the Fed, the June hike seems to have dented any hope for a potential cut in interest rates in September. The total crypto market cap stood at $3.88 trillion at the time of writing. Bitcoin, Ethereum, XRP tumble on shocking inflation report first appeared on TheStreet on Jul 31, 2025 This story was originally reported by TheStreet on Jul 31, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer
WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT, RBOT WS) (the 'Company'), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Stephen From as Chief Executive Officer and a member of the Company's Board of Directors (the 'Board'), effective August 7, 2025. Adam Sachs, current Chief Executive Officer, Co-Founder, and a member of the Board, will remain with the Company as President, Co-Founder, and a member of the Board in an operational capacity as a member of the Company's leadership team. Mr. From brings over 20 years of leadership in the healthcare and financial industry. He most recently served as CEO of Aruna Bio, guiding the company's strategic direction and clinical advancement of its proprietary neural exosome platform. From October 2005 through February 2021, Mr. From served as President and CEO, and from February 2021 through January 2022 served as Executive Chairman of Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), formerly known as EyeGate Pharmaceuticals, Inc., leading the company through its initial public offering and multiple acquisitions and licensing transactions in the ophthalmic therapeutics space. Before EyeGate, Mr. From was CFO of Centelion SAS, then a biotech subsidiary of Sanofi‑Aventis, and spent several years in investment banking, focusing on the life sciences sector at Bank of America Securities and Robertson Stephens. Mr. From holds a Bachelor of Science from the University of Western Ontario and earned his accounting designation from Wilfrid Laurier University 'I am honored to join the Vicarious Surgical team at this pivotal time in its evolution. The Company's technology offers a significant advancement from today's surgical approaches with the potential to transform modern surgery and improve outcomes for patients worldwide,' said Mr. From. 'I look forward to working alongside this talented team and Board to advance our strategic priorities and deliver on the promise of this innovative platform.' 'It has been an incredible journey to lead Vicarious Surgical from its inception through pre-clinical testing, and I'm proud of all we've accomplished to date. As I transition into the role of President, I'm excited to welcome Stephen as our new CEO,' said Adam Sachs, current Chief Executive Officer, Co-Founder, and Board member. 'I believe his leadership and experience are exactly what we need at this pivotal stage, and I look forward to working closely with him to advance our mission of transforming surgical care through innovative robotics.' In connection with the appointment of Mr. From, the Company is also announcing, as required by New York Stock Exchange Listed Company Manual Rule 303A.08 (the 'Inducement Rule'), a stock option award to be made to Mr. From as a material inducement to his entering into employment with the Company. The stock option award was approved by the Company's Board and by its Compensation Committee with a grant date of August 7, 2025. The stock option to be granted to Mr. From will be exercisable for up to 297,600 shares of the Company's Class A common stock, will have an exercise price equal to the closing price of the Class A common stock on the date of grant, and will expire on the ten-year anniversary of the grant date. One-quarter of the stock options will vest and become exercisable on the one-year anniversary of the grant date, and the remainder of the stock options will vest in thirty-six equal consecutive, equal monthly installments thereafter, subject to Mr. From's continued service to the Company through each vesting date and subject to accelerated vesting in certain circumstances. The stock option award will be made outside of the Company's existing 2021 Equity Incentive Plan, as amended (the 'Plan'), but will be subject to terms and conditions generally consistent with those in the Plan, other than with respect to such terms and conditions intended to comply with the Inducement Rule. About Vicarious Surgical Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company's novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla's Khosla Ventures, Innovation Endeavors, Jerry Yang's AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang's E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. The Company's actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the potential for the Company's technology to improve patient outcomes, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company's Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company's initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company's product and service development activities; the potential attributes and benefits of the Company's product candidates and services; the Company's ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company's ability to identify, in-license or acquire additional technology; the Company's ability to maintain its existing license, manufacture, supply and distribution agreements; the Company's ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company's business, financial condition and results of operations; the Company's intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company's filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Business Wire
2 hours ago
- Business Wire
STAAR Surgical to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the second quarter ended June 27, 2025, on Wednesday, August 6, 2025 after the market close. The Company will also host an earnings call and webcast at 4:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical 2Q 2025 Financial Results Webcast Time: 4:30 p.m. ET Location: The live webcast, including an option to pre-register, can be accessed at the preceding link or the 'Investors' section of the STAAR website at A webcast replay will be available at the same link for at least 90 days. About STAAR Surgical STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically-proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 3 million ICLs in over 75 countries. Headquartered in Lake Forest, California, the company operates research, development, manufacturing, and packaging facilities in California and Switzerland. For more information about ICL, visit To learn more about STAAR, visit We intend to use our website as a means of disclosing material non-public information about the Company and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections at Accordingly, investors should monitor such portion of our website, in addition to following our press releases, SEC filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the News & Alerts section at
